Wysa
FDA Breakthrough-designated AI mental health companion delivering CBT support across 95 countries, 24/7
Overview
Wysa is a clinically validated, AI-powered mental health chatbot that delivers evidence-based cognitive behavioural therapy (CBT), dialectical behaviour therapy (DBT), and mindfulness tools via a conversational interface on iOS and Android. Founded in 2015 in Bangalore by Jo Aggarwal and Ramakant Vempati, the platform received FDA Breakthrough Device Designation in May 2022 for its AI-led conversational agent targeting chronic musculoskeletal pain co-occurring with depression and anxiety. As of 2026, it has served more than 6 million people across 95 countries with over 550 million conversations, and is deployed across 31 NHS Talking Therapies services in the UK — where 117,000+ patients have used its Digital Referral Assistant since 2022.
Beyond its consumer freemium app, Wysa operates an enterprise business (Wysa for Enterprise, Wysa Assure, and the Wysa Copilot hybrid human-AI platform launched November 2024) used by insurers, health systems, and employers. MassMutual became the first US insurer to offer Wysa Assure to policyowners in October 2024, co-developed with Swiss Re. In 2025, Wysa expanded aggressively into the US market by acquiring behavioural health provider April Health (March 2025) and physical therapy company Kins (September 2025), positioning itself as a mind-body integrated care platform. Wysa also received a USD 3.4 million NIH grant in 2025 for personalised mental health support for chronic pain.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 16 Jun 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
What you can produce with Wysa
- Daily mood tracking with PHQ-9 and GAD-7 aligned outcome measurement
- 150+ guided CBT, DBT, and mindfulness exercises accessible in-app
- AI-driven crisis detection with escalation routing to human support
- Wysa Copilot dashboard for therapists to prescribe tools and monitor patient progress between sessions
- Enterprise anonymised population analytics for HR and clinical teams
- Automated patient intake and self-referral workflow for health systems (Digital Referral Assistant)
- Multilingual support including English, Spanish, Hindi, Marathi and additional Indian regional languages
ASEAN Perspective
Wysa in Southeast Asia
Wysa has genuine roots in South Asia — founded in Bangalore, with multilingual support that includes Hindi, Marathi, and other Indian regional languages, and a Singapore national health cluster pilot during COVID-19 (2020–2022). However, dedicated localisation for Southeast Asian markets (Bahasa Indonesia, Filipino, Thai, Vietnamese) remains limited, and regional enterprise pricing has not been publicly disclosed, making B2B adoption in ASEAN health systems uncertain. The platform's recognition at the India AI Impact Summit 2026 reinforces its APAC credibility, but ASEAN users outside India and Singapore will find both language coverage and local clinical partnerships thinner than in the UK or US markets.
Wysa stands out as one of the most clinically credible AI mental health tools available: its FDA Breakthrough Device Designation, peer-reviewed efficacy studies, and proven NHS deployment at scale (117,000+ patients across 31 services) give it a level of regulatory and clinical legitimacy that few consumer wellness apps can match. The freemium model keeps the core chatbot accessible to anyone with a smartphone, and the 150+ evidence-based exercises cover a genuine breadth of CBT, DBT, and mindfulness content. The 2025 acquisitions of April Health and Kins signal a serious push toward integrated hybrid care rather than a standalone app.
The main caveats are coverage gaps and positioning questions. Wysa is not a replacement for clinical therapy and is most effective for mild-to-moderate symptoms — the 19% clinical recovery rate from NHS data, while meaningful, should be read alongside what it does not address. The premium tier at approximately USD 29.99/month is moderately expensive relative to regional purchasing power in much of ASEAN, and the enterprise API is closed and custom rather than a self-serve developer product. Free tier limitations (session caps, no crisis detection) mean that the most vulnerable users may face friction just when they need the most support.
What people say
Wysa earns clinical credibility through peer-reviewed evidence and real-world NHS deployments, not just marketing. NHS data show meaningful reliable improvement in anxiety and depression alongside high referral completion, and independent trials found outcomes comparable to in-person counselling for chronic pain and anxiety. The free tier is genuinely useful for daily self-management, but session limits push serious clinical use toward paid plans. For enterprise and health-system buyers, the FDA Breakthrough Device Designation, DCB 0129 NHS certification, and 2025 moves to acquire April Health (a merger, Wysa surviving) and Kins substantiate a clinical-grade platform rather than a wellness app.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Wysa's AI penguin mascot was deliberately designed to feel non-threatening — early user research found people disclosed more to an animal persona than to a human avatar.
- Over 91% of patients who used Wysa's NHS Digital Referral Assistant completed their self-referral — a 25-percentage-point improvement over previous baseline rates.
- Wysa received its FDA Breakthrough Device Designation in May 2022, making it one of the first AI mental health chatbots to reach that regulatory milestone.
- Swiss Re co-created Wysa Assure specifically as an insurance-embedded mental health product — a first-of-kind model that MassMutual adopted in October 2024.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Wysa's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Wysa unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Wysa directly →
Spotted something out of date? Suggest an update →
More in Other
